Ocular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. ACN

Go back to Ocular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

November 5, 2021 9:00 AM EDT

DEXTENZA® to Maintain Separate Payment via Pass-Through Payment Status Through 2022

CMS Indicates DEXTENZA Meets Criteria for Separate Payment after Pass-Through Period Ends

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022.

The OPPS... More